Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements

Journal of Medicinal Chemistry

Volumn 42, Issue 7, 1999, Pages 1213-1224

  Dragovich, Peter S ^a   Prins, Thomas J ^a   Zhou, Ru ^a   Webber, Stephen E ^a   Marakovits, Joseph T ^a   Fuhrman, Shella A ^a   Patick, Amy K ^a   Matthews, David A ^a   Lee, Caroline A ^a   Ford, Clifford E ^a   Burke, Benjamin J ^a   Rejto, Paul A ^a   Hendrickson, Thomas F ^a   Tuntland, Tove ^a   Brown, Edward L ^a   Meador III, James W ^a   Ferre, Rose Ann ^a   Harr, James E V ^a   Kosa, Maha B ^a   Worland, Stephen T ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(5' METHYLISOXAZOLE 3' CARBONYL)VALYL PSI PHENYLALANYL (4F) [PYRROLALANYL]]PROPENOIC ACID ETHYL ESTER; 3 [(5' METHYLISOXAZOLE 3' CARBONYL)VALYLPHENYLALANYL (4F) [PYRROLALANYL]]PROPENOIC ACID ETHYL ESTER; CYSTEINE; GLUTAMINE; LACTAM; PIRODAVIR; PLECONARIL; PROTEINASE INHIBITOR; RUPINTRIVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN RHINOVIRUS; MOLECULAR MODEL; STEREOCHEMISTRY;

ANTIVIRAL AGENTS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLUTAMINE; HUMANS; ISOXAZOLES; LACTAMS; MODELS, MOLECULAR; MOLECULAR MIMICRY; OLIGOPEPTIDES; PYRROLIDINONES; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 0033535596     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9805384     Document Type: Article

References (41)

1. (a) Couch, R. B. In Fields Virology, 3rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., et al., Eds.; Lippincott-Raven Publishers: Philadelphia, 1996; Vol. 1, Chapter 23, pp 713-734.
2. (b) McKinlay, M. A.; Pevear, D. C.; Rossmann, M. G. Annu. Rev. Microbiol. 1992, 46, 635.
3. (c) Phillpotts, R. J.; Tyrrell, D. A. J. Br. Med. Bull. 1985, 41, 386.
4. (d) Gwaltney, J. M. In Principles and Practices of Infectious Diseases; Mandell, G. L., Douglas, R. G., Bennett, J. E., Eds.; John Wiley & Sons: New York, 1985; Chapter 38, pp 351-355.
5. (e) Gwaltney, J. M. In Viral Infections of Humans; Evans, A. S., Ed.; Plenum Publishing Corp.: New York, 1982; Chapter 20, pp 491-517.
6. (a) Rueckert, R. R. In Fields Virology, 3rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., et al., Eds.; Lippincott-Raven Publishers: Philadelphia, 1996; Vol. 1, Chapter 21, pp 609-654.
7. (b) Kräusslich, H.-G.; Wimmer, E. Annu. Rev. Biochem. 1988, 57, 701.
8. (a) Cordingley, M. G.; Callahan, P. L.; Sardana, V. V.; Garsky, V. M.; Colonno, R. J. Substrate Requirements of Human Rhinovirus 3C Protease for Peptide Cleavage in Vitro. J. Biol. Chem. 1990, 265, 9062-9065.
9. (b) Orr, D. C.; Long, A. C.; Kay, J.; Dunn, B. M.; Cameron, J. M. Hydrolysis of a Series of Synthetic Peptide Substrates by the Human Rhinovirus 14 3C Proteinase, Cloned and Expressed in Escherichia coli. J. Gen. Virol. 1989, 70, 2931-2942.
10. (c) Cordingley, M. G.; Register, R. B.; Callahan, P. L.; Garsky, V. M.; Colonno, R. J. Cleavage of Small Peptides In Vitro by Human Rhinovirus 14 3C Protease Expressed in Escherichia coli. J. Virol. 1989, 63, 5037-5045.
11. 2′, etc.) is described in the following: Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
12. Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. R.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E. V.; DeLisle, D. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure-Activity Studies. J. Med. Chem. 1998, 41, 2806-2818.
13. Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, D. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure-Activity Studies. J. Med. Chem. 1998, 41, 2819-2834.
14. A similar series of HRV 3CP inhibitors has also recently been described. See: Kong, J.-s.; Venkatraman, S.; Furness, K.; Nimkar, S.; Shepherd, T. A.; Wang, Q. M.; Aubé, J.; Hanzlik, R. P. Synthesis and Evaluation of Peptidyl Michael Acceptors That Inactivate Human Rhinovirus 3C Protease and Inhibit Virus Replication. J. Med. Chem. 1998, 41, 2579-2587.
15. Preceding paper in this issue. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure-Activity Studies of Ketomethylene-Containing Peptidomimetics. J. Med. Chem. 1999, 42, 1203-1212.
16. All amino acids described in the text are L-isomers unless otherwise noted.
17. Note that the reduction in the antiviral potency of 2 (or 3) relative to 1 was not nearly as great as the loss in 3CP inhibition activity. This observation suggested that Gln amide N-alkylation may result in improved cell permeability properties.
18. obs/[I] values approximate changes in ligand-3CP binding affinity and that the anti-3CP activities of cis-and trans-Z are similar to those displayed by compounds 1 and 3, respectively.
19. Jorgensen, W. L.; Gao, J. Cis-Trans Energy Difference for the Peptide Bond in the Gas Phase and in Aqueous Solution. J. Am. Chem. Soc. 1988, 110, 4212-4216 and references therein.
20. 50 values.
21. 5 for the glutamine-derived molecule 1 (Matthews, D. A. Unpublished results).
22. Dragovich, P. S.; Zhou, R.; Skalitzky, D. J.; Fuhrman, S. A.; Patick, A. K.; Ford, C. E.; Meador, J. W., III; Worland, S. T. Solid-Phase Synthesis of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Optimization of Tripeptideg Incorporating N-Terminal Amides. Bioorg. Med. Chem., in press.
23. 90 of approximately 0.10 μM. Full details of these experiments will be presented elsewhere (Patick, A. K. Manuscript in preparation).
24. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P. A. J. In Vitro Activity of Pirodavir (R 77975), a Substituted Phenoxy-Pyridazinamine with Broad-Spectrum Antipicornaviral Activity. Antimicrob. Agents Chemother. 1992, 36, 100-107.
25. (a) Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J.; Aldous, S. C.; Aldous, D. J.; Robinson, D. T.; Draper, T.; Dutko, F. J.; Aldi, C.; Gendron, G.; Oglesby, R. C.; Volkots, D. L.; Reuman, M.; Bailey, T. R.; Czerniak, R.; Block, T.; Roland, R.; Oppermann, J. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism. J. Med. Chem. 1995, 38, 1355-1371.
26. (b) Fromtling, R. A.; Castañer, J. VP-63843. Drugs Future 1997, 22, 40-44.
27. The α,β-unsaturated carboxylic acids corresponding to the compounds in Table 3 are assumed to exhibit drastically reduced antirhinoviral activity by analogy to data obtained for inhibitor 1. See ref 5 for additional details.
28. The assumption that rat plasma degradation of 11 primarily affords the corresponding α,β-unsaturated carboxylic acid is based on the related degradation of compound 1. See ref 5 for additional details.
29. Mammen, M.; Shakhnovich, E. I.; Whitesides, G. M. Using a Convenient, Quantitative Model for Torsional Entropy To Establish Qualitative Trends for Molecular Processes That Restrict Conformational Freedom. J. Org. Chem. 1998, 83, 3168-3175.
30. Chida, N.; Tobe, T.; Okada, S.; Ogawa, S. Total Synthesis and Absolute Configuration of Bengamide A. J. Chem. Soc., Chem. Commun. 1992, 1064-1066.
31. Ho, G.-J.; Mathre, D. Lithium-Initiated Imide Formation. A Simple Method for N-Acylation of 2-Oxazolidinones and Bornane-2,10-Sultam. J. Org. Chem. 1995, 60, 2271-2273.
32. Evans, D. A.; Rieger, D. L.; Jones, T. K.; Kaldor, S. W. Assignment of Stereochemistry in the Oligomycin/Rutamycin/ Cytovaricin Family of Antibiotics. Asymmetric Synthesis of the Rutamycin Spiroketal Synthon. J. Org. Chem. 1990, 55, 6260-6268 and references therein.
33. 1H NMR spectra of 18 and subsequent synthetic intermediates.
34. (a) Mancuso, A. J.; Swern, D. Activated Dimethyl Sulfoxide: Useful Reagents for Synthesis. Synthesis 1981, 165-185.
35. (b) Tidwell, T. T. Oxidation of Alcohols by Activated Dimethyl Sulfoxide and Related Reactions: An Update. Synthesis 1990, 857-870.
36. (c) DeCamp, A. E.; Kawaguchi, A. T.; Volante, R. P.; Shinkai, I. Stereocontrolled Addition of Propionate Homoenolate Equivalents to Chiral α-Amino Aldehydes. Tetrahedron Lett. 1991, 32, 1867-1870.
37. Mori, S.; Iwakura, H.; Takechi, S. A New Amidoalkynylation Using Alkynylzinc Reagent. Tetrahedron Lett. 1988, 29, 5391-5394 and references therein.
38. Overman, L. E.; Osawa, T. A Convenient Synthesis of 4-Unsubstituted β-Lactams. J. Am. Chem. Soc. 1985, 107, 1698-1701 and references therein.
39. During the preparation of 6, the diastereomeric excess of the allylic alkylation product corresponding to 18 was also not rigorously determined. See ref 25 above.
40. 1 Glutamine Isosteric Replacements. J. Med. Chem. 1998, 41, 2786-2805.
41. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.